The Jackson Laboratory (JAX) and the New York Stem Cell Foundation (NYSCF) have officially launched their unified organization in Manhattan, marking a significant milestone in biomedical research. This collaboration was celebrated with a ceremony attended by nearly 170 prominent figures from academia, industry, and government, underscoring the initiative’s broad support and potential impact.
Lon Cardon, PhD, JAX president and CEO, emphasized the transformative potential of this partnership, stating, “When you bring together JAX’s leadership in mouse and cell biology with NYSCF’s pioneering innovation in human stem cells and automation, something truly unique begins to take shape.” This integration aims to harness genetic insights to enhance human health, exemplified by the rapid development of a custom gene therapy for a child with a rare disorder, Baby KJ.
The acquisition of NYSCF by JAX in October has created a robust nonprofit engine for biomedical discovery, merging JAX’s extensive genetics expertise with NYSCF’s advanced stem cell technologies. This strategic unification is expected to facilitate large-scale, reproducible research and empower scientists to develop more precise treatments tailored to individual patients, thus advancing the field of personalized medicine.
Get started today with Solo access →
